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Purpose/Objective: Focal boosting in radiotherapy for 
prostate cancer aims at improving tumor control without 
increasing side effects by giving a high dose to the index 
lesion only. Here, an accurate delineation of the tumor is 
essential. Manual delineations are time consuming and vary 
among observers. Recently a model has been published for 
automatically delineating tumors in the peripheral zone using 
multi-parametric MRI (Model 1). The model that was trained 
on a database of 87 radiotherapy patients. Here we perform 
an independent validation of this model with and without 
updating its parameters using data from independent centers 
to investigate the robustness of this model w.r.t. different 
equipment and scan protocols. 
Materials and Methods: The study involves 18 patients 
(database A) from the first center and 17 patients (database 
B) from the second center (Table 1). There are one and three
patients from A and B, respectively, of whom index lesions 
are not in the peripheral zone. Prior to prostatectomy, all 
patients received MRI, including T2-weighted (T2w), 
diffusion-weighted (DWI), and dynamic contrast enhanced 
(DCE) sequences. The MRI protocols differ among the centers 
and are not intended for quantitative evaluation. 
Hematoxylin and Eosin stained slices were obtained from the 
prostate specimens, on which a pathologist delineated the 
tumors. These slices were registered to the T2w images and 
then used as ground truth for evaluation. Voxels within ±1.25 
mm margin of the pathological tumor contour were ignored 
to reduce the influence of registration errors. Model 1 is a 
logistic regression model which predicts the probability of 
tumor presence using ADC, Ktrans, and coordinate features. 
We compare the performance of Model 1 and two retrained 
models, A and B, created by fitting the coefficients of Model 
1 on databases A and B, respectively. The retrained models 
are tested using a leave-one-patient-out cross validation. 
Results: Model 1 correctly detects 16 of 17 and 13 of 14 
index lesions on databases A and B, respectively. However, it 
introduces 7 and 8 false alarms. The T1w images indicate 
that the tumor missed in database A might be obscured by 
post-biopsy hemorrhage effects. The tumor missed in 
database B is sparse on histology, and therefore difficult to 
detect on MRI. Figure 1 shows an example of the 
classification results. 
On database A, models 1 and A produce average AUC values 
of 82.2% and 83.6%, respectively. On database B, models 1 
and B produce average AUC values of 73.6% and 77.6%. That 
means the retrained models perform slightly better than 
Model 1, however, the difference in AUC is not statistically 
significant. 
Conclusions: Model 1 provides comparable results to the re-
trained ones, i.e., it is robust to differences in scan protocol. 
This suggests that the model can be implemented widely as 
additional diagnostic tool for radiation oncologists to 
delineate focal lesions in prostate.  
